Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor

Citation

• Hutson, T. E., Davis, I. D., Machiels, J. H., de Souza, P. L., Baker, K., Bordogna, W., . . . Figlin, R. A. (2008). Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. Journal of Clinical Oncology, 26(15_suppl), 5046. doi:10.1200/jco.2008.26.15_suppl.5046

Digital Object Identifier (doi)

• 10.1200/jco.2008.26.15_suppl.5046

Web Of Science Accession Number

Start Page

• 5046

End Page

• 5046

Volume

• 26

Issue

• 15_suppl

Place Of Publication

Abstract

UOW Authors

•   De Souza, Paul (external author)

Publication Date

• 2008

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Hutson, T. E., Davis, I. D., Machiels, J. H., de Souza, P. L., Baker, K., Bordogna, W., . . . Figlin, R. A. (2008). Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. Journal of Clinical Oncology, 26(15_suppl), 5046. doi:10.1200/jco.2008.26.15_suppl.5046

Digital Object Identifier (doi)

• 10.1200/jco.2008.26.15_suppl.5046

Web Of Science Accession Number

Start Page

• 5046

End Page

• 5046

Volume

• 26

Issue

• 15_suppl

Place Of Publication